Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV 001 versus placebo in active thyroid eye disease
NL-OMON41037Phase 2Withdrawn
- Sponsor
- River Vision Development Corp.
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED) comparing RV 001 with Placebo (2 arms). Primary endpoint: Responder status at week 24. Planned start Sep 2014; status: withdrawn.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NL-OMON41037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41037.